Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare Biotechnology

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > Trial update

<< Previous

Bullboard Posts

Next >>

Comment by 1ottrunneron May 06, 2021 7:42am

77 Views

Post# 33138967

RE:RE:RE:RE:RE:RE:RE:RE:Trial update

On the OTC? lol

TheTerminator1 wrote: Once RVV's SP reaches $2,will it become marginable?

1ottrunner wrote: Positive results would have a great impact on SP, I would not be surprised to see $2.

The chance of seeing positive results based on what the Colchicine trial put up, with the same method of action? 20% is gracious.

If the trial is successful the news will be picked up nationally.

Towser7 wrote:
Completely agree. I worry that even positive results will have an underwhelming impact on SP. whether that's because it's too late or just not properly covered/promoted it is a fear.